For so many people PT-141 Peptides have been a saviour as far as erectile dysfunction is concerned. Other related sexual problems are also concerned. The aim of this article is to ensure that you, the reader will easily understand what PT-141 Peptides can and will do for you. So stop the suffering now by simply following these steps and get your life back now!
If you want to skip this article and >>>BUY PT-141 Peptides now – Click Here<<<
What is PT-141 Peptide?
PT-141 (Bremelanotide) is a cyclic heptapeptide lactam analog of α-MSH (α-melanocyte-stimulating hormone) with the amino acid sequence Ac-Nle-cyclo [Asp-His-D-Phe-Arg-Trp-Lys] -OH and medium elimination half-life 2.7 hours. It is an active metabolite of Melanotan 2 peptide, which is lacking in the C-terminal amide, however, PT-141 does not significantly stimulate melanotogenesis (increased pigment formation) unlike Melanotan 2.
This peptide mainly greatly increases and stimulates libido, sexual arousal and sexual activity in men and women. PT-141 can be used to treat generalized hypoactive sexual desire disorder (HSDD), erectile dysfunction (ED) in men, even in men who have not responded to other treatments for erectile dysfunction such as Viagra, Cialis, etc. .) and similar sexual arousal disorders. PT-141 (Bremelanotide) has been officially approved for medical use in the United States since 2019.
What is Bremelanotide?
Bremelanotide (PT-141) developed by Melatonan 2 (MT-II). PT-141 is a metabolite of melanocytes that stimulates the desire hormone.
What is Bremelanotide used for ?
Treatment of erectile dysfunction : PT-141 is the only synthetic aphrodisiac available on the market. The stimulant effects of bremelanotide can only fall into its own ranking, as there is no analogue.Studies show that bremelanotide is highly effective in the treatment of sexual dysfunction in both men (erectile dysfunction or impotence) and women (frigidity). In clinical trials, nine out of ten volunteers experienced sexual arousal. Compared to Viagra and other similar drugs (PDE5 – blood stimulants), PT-141 acts directly on the nervous system. Viagra, Cialis and Levitra do not belong to the group of aphrodisiacs, as these are drugs without a direct effect on the nervous system. On the other hand, treatment with PDE5 and PT-141 inhibitors has a synergistic effect.
PT-141 Peptides Reviews
Men’s Journal Magazine: “Its impact was palpable. I felt a strong surge of sexual attraction (much stronger than the usual levels of arousal). My body was shaking with desire and I got an erection, which was impressive. For two hours, the action didn’t diminish, and my wife and I had a memorable experience. ” “Frederick Kaufman.”
Women: Women in the tests claim to have “throbbing thrills” and “burning desire for sex.” The initial influx is felt immediately after the injection, nausea may follow, which is highly dose dependent. In many people, the effect is usually not felt immediately and at least an hour after the injection, and peaks around the fourth hour.
Men claim that PT-141 rejuvenates them and gives them a surge of energy, increases sexual desire and arousal. “After taking it, you are ready to just take off your pants and act without interruptions,” says a user. He also shares: “this is a medicine that not only gives you the opportunity physically, but also makes you want it, by directly affecting the mind.”
Bremelanotide PT-141 is a peptide : Bremelanotide is available in 10 ml ampoules. It is a peptide that improves lifestyle and lifestyle, the 10 mg ampoule is large and is sufficient for up to 20 doses if taken in moderation. Peptide PT-141, mixed with bacteriostatic water, retains its quality when stored properly in the refrigerator for months.
Immediate possibility : When injected subcutaneously, bremelanotide has an immediate effect lasting from 6 to 72 hours. In the laboratory, tests on female rats subjected to PT-141 began flirting with males and seeking sexual intercourse. The duration and mode of sexual intercourse in experimental animals leave no doubt that this is a consequence of taking the drug. In humans, for effective action, it is recommended that PT-141 be taken at least two hours before sexual intercourse. This is enough time to prepare and enjoy the moment.
Mixing: Bacteriostatic water
Example: 1 ml (cc) of bacteriostatic water per 10 mg PT-141 equals 1 mg dose, approximately in each of the 10 divisions of a U100 insulin syringe.
Example: 1 ml (cc) of bacteriostatic water per 2 mg PT-141 equals 1 mg dose, approximately every 50 divisions per insulin U100 syringe.
How to act if we are about to have a love affair to be in shape ?:
The recommended mixing and dosing strategy would be to add a volume from which to inject 1 ml.
Example: 1 ml (cc) of bacteriostatic water per 10 mg PT-141 equals 1 mg dose, approximately each of the 10 divisions of a U100 insulin syringe.
Example: 2 ml (cc) of bacteriostatic water per 2 mg PT-141 equals 1 mg dose, approximately every 50 divisions of a U100 insulin syringe.
Find out as much as possible from different sources to be aware of what effects you can expect. Gradual and correct dosing is the best way to have a positive effect without side effects. It is recommended that the first test dose be 0.25 – 0.5 mg. 1 mg, plus or minus a quarter is the dose that is most effective and receives the highest response among users who have used the drug.
According to the Journal of the American Medical Association, more than 43% of American women (approximately 40 million) suffer from some form of sexual dysfunction. “This is a significant problem for the working age population and we must pay attention to talk about it openly.”
At the Medical Center for Female Sexuality, they often have to apply treatment in case of hypo sexual desire or suppressed libido. Effective therapies are prescribed, but most are outside the official prescriptions. “Forms of sexual dysfunction are constantly changing and expanding. We are actively working towards their control and return to normal, so that young women can lead a full life. We are currently testing with a new drug called bremelanotide.
The drug was originally called the “Barbie pill”. The reasons for this are that some of the side effects that are tempting for women are: weight loss, light skin toning and a fresh, radiant complexion and increased sexual desire. What more could a woman want? Of course, like any other synthetic preparation, this one has its side effects. That is why the tests are carried out very carefully and the dosage should be followed according to the prescriptions for safe administration. ”
Bremelanotide (RT-141) – dosage and action
Moderate dosage of PT-141 (250mcg-500mcg):
“I used a dose of 0.4 mg at 10:00 in the evening and had a series of erections throughout the night that lasted until 7 in the morning. In my own experience, a small dose is most effective if given at night before bed. The only problem with frequent erections is that it affects sleep. And the other is that the probability of getting an erection without having a desire or a partner next to you, the effect is lost.
Another thing I found out about myself is that even at small doses of 0.3 mg a day I get sexual fantasies. It may have a psychological effect on me, but just the thought of taking the drug evokes sexual fantasies. ”
Usual dosage of PT-141 (~ 1 mg subcutaneously):
“My girlfriend and I were separated for a while and before we saw each other I decided to take 10 units (0.1 ss) on Thursday around eight in the evening. It took a while for it to take full effect (about 6 hours), but when that happened the feeling was unique. I got a series of erections all night, which lasted until noon the next day. ”
“I used 50 units of PT-141 in a diabetic syringe to get 1 mg. I am 72 years old and I have been suffering from impotence for several years now, and this preparation gave me confidence that I am still good. The combination of bremelanotide and half a dose of viagra gives me unshakable confidence (only viagra would not get an erection that lasts until orgasm). The very feeling of sexual power gives me a great deal of confidence and makes me feel like a real man again. I am one of the lucky ones who have not studied side effects so far. Weight 90 kg. and I have never taken more than 1.2 mg. Maybe in the future I will increase by 1.5 mg. ”
“My initial dose of 1.5 mg was too high. My erection lasts 8-10 hours. I took the dose at 7 pm, and the effect was felt at 11: 30-12: 00 OVERNIGHT. ”
“I am 55 years old, 77 kg, in post-menopause, I injected myself with 1.7 mg. My husband is 55 years old, 68 kg, he injects himself with 1.2 mg. Ampoule of 10 mg mixed with 1 ml of bacteriostatic water. We both experienced slight redness and nausea, which lasted for about 10 minutes after the injection. The side effects lasted no more than 15 minutes. 3 hours later, bremelanotide (RT-141) literally blew us up. We were in a restaurant, I began to feel hot flashes of sexual arousal, my senses sharpened and my husband had difficulty getting up from the chair, he had an impressive erection. We had not judged the time of admission and put ourselves in an awkward situation.
But in the end we got increased sensitivity, pleasure experienced with all the senses, a series of erections for hours and many mind-boggling orgasms! About us Viagra, Cialis, etc. are just out of the game. ”
“I took 1 mg of PT-141 on the first night, and the effect was not long in coming. I felt a rush of shivering heat, and I was ready for a long, naughty night. My husband also used 1 mg, combining it with 20 mg of Cialis. After the “Wow” effect, we fell asleep pleasantly tired and very happy. At 2:00 in the morning I woke up from a long-forgotten feeling, I had to have sex and I didn’t take “no” for an answer. Not that my husband was complaining, and these were the most exciting orgasms we’ve ever had.
At 6 pm we decided to try again and decided to try another dose of PT-141. Although the effect lasted for about 3 days, I wanted to experiment. An hour later I was so aroused that I could barely contain myself. We put the child to bed earlier and indulged in the pleasure. As I said, the effect of the drug takes about 4 hours, but taking the second dose only 24 hours after the first really had an effect, I was very excited and thank God, our son fell asleep quickly.
The rest of the weekend was indescribably exciting to say the least, I was insatiable and my husband was able to give me everything I needed. I lived with the thought that the sexual thrill was a thing of the past, but the RT-141 opened a new chapter in our relationship. ”
“I got my first ampoule of 10 mg and started with 0.25 mg, gradually increasing the dosage by 0.25 mg. At first I got a slight redness and got the desired effects, reaching 1 mg. Then I had to travel and stopped using the drug for about 2 weeks. The mixture seems to reduce its effect after 6 weeks of reconstitution, but I still liked it so much that today I ordered three more ampoules of 10 mg. I am 64 years old and I did not expect such sexual achievements at this age. Wow! ”
High dose of PT-141 (~ 2 mg):
The high dose of PT-141 in most cases leads to numbness in the groin, with an average duration of about fifteen minutes. According to some results, women feel “warming in the groin, throbbing and tingling”, not to mention “increased sexual desire”. In men undergoing more thorough drug tests, the data are more comprehensive:
“On Friday around 5 pm, I took 20 units (0.2 ss). By 10 I already had an indescribable erection and I had great sex. As the others noted, I felt 18 again. We did it again around midnight and even then I kept getting erections all night. On Saturday, after training, I took another 10 units and my girlfriend and I had a great weekend. For me, this really turned out to be life-saving. If you have any concerns about your sexuality, I highly recommend you give it a try. In my case, I had nothing to lose, but I hit the jackpot. I have no words to describe my enthusiasm for this product. ”
“I took 2 mg around 5:45 in the evening (I weigh about 95 kg and I am 173 cm tall). I felt a rush of blood in my face and stomach upset for the next few hours. I didn’t have time to rest and relax after the injection. Instead, I spent my usual work evening. Around 10 pm we had a sexual game with my wife. I didn’t find much difference between the usual course of events and then, but it was a great experience with almost no effort on my part.
Then, around 11:30 a.m., about 5 hours after the injection, spontaneous erections and a general feeling of satisfaction. My wife was asleep and we were already having sex, so I had to take care of myself. The rest of the night was pretty restless as I kept waking up from my erections. I took care of myself again at 6:30 in the morning.
I had problems most of the morning. Not a good time when it was crowded with children rushing to school while I was trying to work. I need to change the timing of the dose. In the end, I’m not complaining, the action of bremelanotide (PT-141) subsided around 1 in the afternoon. ”
“RT-141 makes you feel good physically and mentally, it doesn’t just excite you,” said anonymous patient 007, who participated in phase 2 of the trial period, “You feel rejuvenated and full of energy.”
Another patient claims: ” It not only helped the libido, it strengthens the desire… You get this vibrating feeling, you are ready to take off your pants and start .”
And another satisfied user: “My wife and I had sex two nights a night. I arrived at work and just couldn’t stand it and bragged, “Lord boys… At 58, do this!”
Selective facilitation of sexual desire in the female rat by the melanocortin receptor agonist
Summary Bremelanotide PT-141
Sexual dysfunction affects about 30% of women in North America and Europe, including etiologies of an interpersonal, personal, and physiological nature. There are currently no approved pharmacological drugs on the market for the treatment of female sexual dysfunction. This is due in part to the focus on the effects of experimental drugs on the reflexive components of sexual behavior. As lordosis in animal test models. Here, PT-141, as a peptide analog of α-melanocyte stimulating hormone that binds to central melanocortin receptors, selectively stimulates sexual behavior in a female test rat. This is done without affecting lordosis, frequency or other sexual behaviors.
PT-141 does not cause generalizing motor activation. Nor does it affect the perception of the sexual reward. No selective pharmacological effect on sexual appetite was observed in female rats. And there are indications that central melanocortin systems play an important role in the regulation of sexual desire in women. In this regard, PT-141 may be the first known pharmacological agent to be able to treat and normalize sexual dysfunction in women.
Neuropeptides derived from proopiomelanocortin (POMC) and including β-endorphin, corticotropin (ACTH) and α-melanocyte-stimulating hormone (α-MSH) have already been shown to have an effect on sexual behavior in rats in experiments. For female rats, α-MSH either facilitates or inhibits the sexually receptive lordosis posture depending on the hormonal status of the animals and whether they are low or high in sexual receptivity, respectively. Estradiol enhances levels of α-MSH in the hypothalamic areas of the brain associated with female sexual behavior, suggesting that the release of α-MSH may be one of several mediators of estrogenic action.
It was recently noted that PT-141, which is a peptide analogue of α-MSH, is erectogenic for men, assuming that it affects central melanocortin receptors of type 3 or type 4 Given the predominant sexual disorders in women and the lack of available pharmacological therapies, we wondered if PT-141 could induce sexual appetite in female rats. In this regard, the present study investigated PT-141 dosing responses associated with receptive sexual behaviors such as prompting, jumping, rushing, and frequency, as well as receptive sexual behaviors such as lordosis in female ovaries with ovaries tested in various hormonal regimens. cameras on two levels, as well as in single frequency cameras.
In the present experiments, frequency cameras were used to make a correct assessment of the sexual behavior of female individuals. ( see above ). The copulation in the two-level chambers, initiated after prompting ( 1 ) and followed by anogenital examination by the female ( 2), escaping the female to the upper level ( 3 ), encouraging the male to pursue her, and finally followed by a demonstration of lordosis by the female ( 4), which allows the male to penetrate it. ( see below ) Copulation in frequency chambers at one level. The female on the left crawls through an opening in the central septum to initiate copulation with the male. The female on the right is possessed.
In 10 preliminary tests for sexual behavior in frequency chambers at one or two levels with sexually active Sterile rats Long-male rats before tests with PT-141. This was done to allow the female to acclimatize to the test procedures and showed stable baseline levels of sexual behavior in previous attempts. The tests were performed at 4-day intervals in the middle of one-third of the dark circadian circle for rats. Complete sexual receptivity was induced by subcutaneous injections of estradiol benzoate (E; 10 μg per 0.1 ml sesame oil) and progesterone (P; 500 μg per 0.1 ml sesame oil) at 48 hours and 4 hours before each test. In the tests, which included only E refueling, sesame oil-diluent was administered 4 hours before the tests.
PT-141, as a cyclic analogue of the heptapeptide melanocortin (Palatin Technologies, Cranbury, New Jersey), was dissolved in saline to obtain doses of 50, 100 and 200 μg / kg / mlm, injected subcutaneously 5 minutes before each behavioral test. The same volume of saline was administered to the test animals.
Behavioral tests. Cameras on two levels
E and P were administered to females (n = 40) and administered randomly to obtain one of the four doses of PT-141 (0, 50, 100 or 200 μg / kg). The females were placed in two-level chambers with the sexually active males for a 30-minute copulation test. All tests were recorded and evaluated effectively using a computerized event recorder. The latency and frequency of prompts (frontal orientation to the male, followed by a sharp escape to the other level), jumps and rushes, frequency (number of shift levels), rejection reactions and lordosis rates were reported for each female. Another group of females treated with E alone (n = 20) were subjected to one of two doses of PT-141 (0 or 200 μg / kg) at random using a repeated measurement model, so they were used as their own controls.
Frequency cameras on one level
A different group of females (n = 40) were injected with E and P and randomly assigned one of four doses of PT-141 (0, 50, 100, or 200 μg / kg). The chambers were separated from each other by plexiglass partitions with four square holes (4 × 4 cm), with holes at the bottom. The size of the openings allowed each female to move freely on the other side, but at the same time they were too small for the males to make them difficult. The females were placed in the chamber along with the sexually active males for a 30-minute copulation test. All tests were re-recorded and evaluated with a computerized event recorder.
The same behavioral measurements were reported as for the two-level chambers with the addition of female-male copulatory initiatives and latencies to leave and return to the ward where the male was after ascending, penetrating, or ejaculating. In this case, the prompting is defined as the frontal orientation of the male, followed by a sharp escape, regardless of whether the female remained in the male’s compartment or exited the barrier.
Females (n = 20) were initialized with E and P, injected with one of two doses of PT-141 (0 or 200 μg / kg) and placed in a chamber (76 cm × 51 cm × 61 cm) filled with 1 litter. cm for a period of 15 minutes. All tests were recorded. The open field was subsequently divided into a 3×3 section on the video screen and the number of section crossings that each female made was recorded. Each female was treated as a separate control unit and the order of drug administration was arbitrary.
Air-conditioned place of preference.
Females (n = 20) were subjected to preliminary testing in order to reveal their essential preference for the apparatus on one of the two distinctive sides of the conditioned preference site (CMP) (light or dark). The females were then allowed to intercourse in the one-level frequency chambers, separated by a Plexiglas barrier with one or four openings for 30 minutes, after which they were placed on one of the distinctive sides of the CMP apparatus for 15 minutes. prefer four-hole intercourse over one-hole intercourse, four-hole intercourse was combined with the internally non-preferred (light) side during training, while single-aperture was combined with the essentially preferred (dark) side.
The expectation was that the female’s preference for the four-aperture camera would outweigh her preference for the dark side of the camera and make her change her preference and spend more time in the light side after conditioning. Conditioning to each country was performed sequentially at 4-day intervals, for each of the three pairs in total. Females from one group were injected with PT-141 (200 μg / kg) 5 minutes before intercourse in the light chamber with four holes and saline before intercourse in the dark chamber with one hole, while females from the other group received PT-141 and physiological solution under exchanged conditions.
The BMD was tested 4 days after the final conditioning experiment by placing each female treated with E + P in the starting compartment at equal distances from the two distinctive sides. The females had the opportunity to examine the CMP box for 10 minutes. The entries in each of the countries were detected by photo-rays and the time spent in each country was recorded between the photo-ray breaks from a high-precision computer.
For the overall dose effect for each measure, data were subjected to unidirectional ANOVA. All significant ANOVA results were followed by Newman-Coyles tests for significance between individual means. For all analyzes, P <0.05 determined significance.
Results Bremelanotide PT-141
Treatment with PT-141 (100 or 200 μg / kg subcutaneously) significantly increased the proactive urges in females treated with E + P or E (E + O) alone in two-level chambers. ,however, without affecting the frequency, lordosis, and other signs of receptivity such as jumps and rushes. The drug has more pronounced effects in females treated with E + P, who have intercourse in frequency chambers with one level, separated by a barrier with four openings. Treatment with the same doses of PT-141 significantly increased urges as well as jumps and rushes but not lordosis. Females in single-level chambers perform more jumps and rushes as a promotional behavior after encouragement. Therefore, we expect this measure to be strengthened at the same time as the incentives in the single-level chambers. Attempts to board males were observed in females treated with the highest dose of PT-141.
The ascent of females to male rats is typical of females primarily treated with E + P, when combined with castrated or sexually inactive males, and this is considered to be proceptive sexual behavior. The latency of escape and return in males after boarding (data not shown) or intromisations is not affected by PT-141. However, the latency of avoidance and recurrence in males after ejaculation is significantly increased after PT-141. Ejaculation typically results in increased return latency, so the effect of PT-141 definitely enhances the effect of ejaculation.
Response to the effect of the PT-141 dose on sexual behavior in two-level chambers. ( above ) Effect of incentives in female subjects primarily treated with estrogen and progesterone (E + P) or estrogen alone (E only). For females treated with E + P, F 3.35 = 3.73, P <0.02. For females treated with E only, F 1.37 = 5.52, P<0.03. Subsequent tests showed that both doses of 100- and 200-μg / kg significantly increased the number of promotions compared to saline-treated controls (P values <0.05). (medium) Frequency effects in females initially treated with E + P or E only. Effects of lordosis rates in females primarily treated with E + P or E only. Data are averaged + SEM. * , P <0.05.
Response of the dosing effect of PT-141 on sexual behavior in female E + P-treated rats in single-level frequency chambers. Effect on promotion ( F 3.34 = 6.62, P <0.002). Direct impact on jumps and rushes ( F 3.34 = 4.12, P <0.02). Subsequent tests revealed that both doses of 100- and 200-μg / kg significantly enhanced incentives, jumps, and rushes ( P values <0.05). Impact on lord coefficientsEffect on female climbs on male (GCM). F 3.34 = 3.84, P <0.02. Subsequent tests revealed a significant effect of only the strongest dose ( P<0.05). Effects of intromission return latency. Effects of ejaculatory latency on return. F 3.34 = 3.65, P <0.02. Subsequent tests showed a significant effect of 100- and 200-μg / kg doses ( P values <0.05). Data are averaged ± SEM. * , P <0.05 from controls.
Studies have been conducted in the open field to examine whether the effects of PT-141 could be caused by an overall increase in mobility, behavioral activity in fully initialized females. The PT-141 did not affect overall mobility, indicating that the increase in incentives was not secondary to the overall increase in behavioral activity. In conclusion, the ability of PT-141 to change the perception of sexual reward induced by frequent intercourse was reported through CPM.
It is noted that females show a preference for a dark compartment over a lighted one. Women perceive frequency intercourse as a reward, and previous research has shown that frequency intercourse combined with a lighted compartment and infrequent intercourse in a dark compartment show a result in shifting the choice to the illuminated compartment during sequential selection tests. The rewarding element in this case is intercourse in a chamber on one level, separated by a plexiglass barrier, which contained four small openings through which the female can pass but not the male. The less preferred condition is the same one-level chamber separated by a plexiglass barrier with a small opening. PT-141 or saline was injected on a balanced basis before copulation in the preferred to non-preferred condition.
RT-141 did not change the normal development of BMD under any of the conditions. This shows that the drug does not enhance the desire for the sexual reward provoked by the four-hole frequency condition, nor does it increase the desire for the sexual reward in the less preferred single-hole frequency condition.
Effects of PT-141 or saline on mobility and BMD. ( Above ) Effects of PT-141 (200 μg / kg) or saline on the number of cross-section sections in the open field during a 15-minute locomotor activity test. ( Below ) Effects of PT-141 or saline on BMD induced by sequential alternation of copulations in the single-hole chamber relative to the four-chamber. Data are averages + SEM. * , P <0.05 from preliminary tests.
Discussion Bremelanotide PT-141
These results show a selective pharmacological enhancement of sexual desire in female rats. They were initially treated with E and P or E alone. Prompting, bouncing, and rushing were previous manifestations of sexual innuendos used by female rats. In this way they attract males. Females who seek and rely on sexual contact over time receive rapid copulatory stimulation from males at desired intervals. Thus increasing the chance of fertilization.
The ability of PT-141 to amplify the call in two distinctive experimental media indicates that its action is selective and stable. This leads to the conclusion that the central melanocortin systems are part of a neurochemical network that causes sexual appetite. As well as behavior in female rats. Here, PT-141 demonstrates high affinity for melacortin receptors types 1, 3, and 4. Without binding particularly strongly to the 30 other neuropeptide or monoamine receptors found in the CNS. At present, the specific areas of the brain on which melanocortins can have such an effect are unknown.
Given that PT-141 is also associated with high affinity for the melanocortin receptor type 1, we cannot rule out the presence of a peripheral mechanism of action. Especially for the increased latency of return after ejaculation. However, the selective binding of PT-141 to type 3 and 4 melanocortin receptors within the CNS has a central effect on the hypothalamic and / or visceral brain structures, similarly controlling the behavior of sexual desire. Increased estrogen-induced activity in the hypothalamic melacortin systems sheds light on the peak in female-initiated sexual behavior. This is typical of many animal species. Including in humans during ovulation. Bremelanotide PT-141
The effects of pharmacological manipulations in behavioral patterns of sexual appetite and consumption were observed to be similar in male rats and males. Despite the fact that sexual behavior in rats is different from that in humans. This finding leads to the conclusion that many aspects of the neurochemistry and neuroanatomy of male sexual responses are similar in different species. This finding allows sexual responses in male rats to be used as models for sexual responses in males.
Behavioral similarities between female rats and females have not been the subject of much study. This is due in part to the concentration on the lord reflex as a defining feature of sexual behavior in female rats. Although lordosis is critical to vaginal penetration and shows that females are receptive to such stimulation. It concerns only one aspect of the behavioral pattern that females demonstrate during copulation. Moreover, in humans there is no analogue of lordosis as a measure of sexual receptivity.
Other behaviors shown by female rats during intercourse are divided between prompting and frequency. And are behaviors that allow females to initiate and regulate the frequency of sexual intercourse. It is true that jumps and rushes are also a trick of females to make males climb them, and these behaviors intensify after treatment with PT-141. To such an extent that the appetite for sexual activity in female rats can be compared to the sexual desire in females. From this we can conclude that PT-141 has the behavioral properties that are expected from pharmacological agents in the treatment of sexual dysfunction and decreased sexual desire.